Contents



Lidia Ciobanu, Attila Tamas Szora, Alexandru Florin Badea, Mihai Suciu and Radu Badea

#### **X** Contents



Preface

Ours is an exciting time. At no other time in history has there been such an exponential in‐ crease in our understanding of disease processes through research and innovation. Kidney cancer is no exception. The recent propulsion and coupling of technological advances and targeted drug therapy in the management of kidney cancer has ushered with it a plethora of significant advances in our current approach. However, kidney cancer continues to impose a significant cancer burden and its incidence continues to rise globally. Mortality in ad‐ vanced kidney cancer remains high despite oncological, surgical and multimodal optimisa‐ tion. Genetic associations, heterogeneity and limitations in early diagnosis through lack of

This book is the first in a series that aims to act as a primer and to provide the reader with a comprehensive and up-to-date framework to optimise understanding and stimulate further research and innovation. The chapters were written by a global faculty of leading experts in the respective fields with a multidisciplinary approach. The authorship includes scientists, pathologists, engineers, surgeons, radiologists, oncologists and innovators. The focus of the book is broad and includes genetics, immunology, virtual augmented reality, surgical simu‐ lation and robotic surgery. Some chapters explore leading edge concepts while others cap‐

The Editors would like to acknowledge the respective authors and sponsors for their hard

National Institute for Health Research (NIHR) Lead for Surgery in Kent, Surrey and Sussex,

**Dr. Sashi S. Kommu**

**Dr. Inderbir S. Gill**

Los Angeles, California, USA

UK

Associate Professor in Uro-oncology and Cancer Biology

Consultant Urological and Minimally Invasive Surgeon East Kent Hospitals University NHS Foundation Trust

Shirley and Donald Skinner Chair in Urologic Cancer Surgery

School of Biosciences, University of Kent

Chair and Distinguished Professor of Urology

Executive Director, USC Institute of Urology Associate Dean for Clinical Innovation University of Southern California (USC)

optimal biomarkers and early detection tools add to the challenges.

ture the evolving trends and future concepts.

work and support in generating this book.

